MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
BeiGene, Ltd. Total Non Current Liabilities 2011-2026 | BGNE
Annual Total Non Current Liabilities BeiGene, Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 B | 374 M | 458 M | 527 M | 803 M | 656 M | 324 M | 250 M | 212 M | 17.8 M | 7.27 M | 14.5 M | 18.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2 B | 7.27 M | 435 M |
Quarterly Total Non Current Liabilities BeiGene, Ltd.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 B | 318 M | 358 M | 374 M | 369 M | 407 M | 426 M | 458 M | 478 M | 525 M | 545 M | 527 M | 660 M | 677 M | 760 M | 803 M | 625 M | 675 M | 705 M | 656 M | 656 M | 656 M | 656 M | 324 M | 324 M | 324 M | 324 M | 250 M | 250 M | 250 M | 250 M | 212 M | 212 M | 212 M | 212 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 7.27 M | 7.27 M | 7.27 M | 7.27 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.13 B | 7.27 M | 388 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.72 | -3.38 % | $ 8.95 B |  Australia |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.92 | - | $ 4.81 M |  Israel |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M |  USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 95.5 | - | $ 27.2 B | Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Precision BioSciences
DTIL
|
62.9 M | $ 6.67 | - | $ 25.6 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 2.17 | - | $ 451 M | USA |
 |
Evogene Ltd.
EVGN
|
5.36 M | $ 0.81 | - | $ 27.9 M | Israel |
|
Forte Biosciences
FBRX
|
10.5 M | $ 35.09 | - | $ 454 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 20.37 | - | $ 952 M | USA |
 |
Galectin Therapeutics
GALT
|
52 K | $ 2.3 | - | $ 147 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
7.22 B | $ 8.21 | - | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
714 K | $ 0.37 | - | $ 2.04 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Halozyme Therapeutics
HALO
|
388 M | $ 67.82 | - | $ 8.13 B | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 32.24 | - | $ 2.14 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
168 M | $ 1.4 | - | $ 360 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.08 | - | $ 436 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 24.21 | - | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Hoth Therapeutics
HOTH
|
2.71 K | $ 0.52 | - | $ 7.18 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.49 | - | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
942 K | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
ImmuCell Corporation
ICCC
|
11.5 M | $ 7.08 | -1.6 % | $ 63.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.55 | - | $ 16 M | USA |
 |
Immutep Limited
IMMP
|
10.9 M | $ 0.31 | - | $ 1.08 B | Australia |
 |
InflaRx N.V.
IFRX
|
254 K | $ 1.0 | - | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
315 M | $ 96.07 | - | $ 18.8 B | USA |
 |
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B | Britain |